The link between vitamin D, chemerin and metabolic profile in overweight and obese children - preliminary results.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 13 01 2023
accepted: 06 04 2023
medline: 9 5 2023
pubmed: 8 5 2023
entrez: 8 5 2023
Statut: epublish

Résumé

Vitamin D affects adipogenesis, oxidative stress, inflammation, secretion of adipocytokines, lipid metabolism and thermogenesis. Some researchers postulate that those effects could be exerted by the influence of vitamin D on chemerin levels. We aimed to investigate if there is a link between serum 25-hydroksyvitamin D [25(OH)D], chemerin and metabolic profile in overweight and obese children before and after vitamin D supplementation. The prospective study included 65 overweight and obese children aged 9.08-17.5 years and 26 peers as a control. None of the patients in the study group had received vitamin D within the last twelve months before the study. The study group had lower baseline 25(OH)D (p<0.001) and higher chemerin (p<0.001), triglycerides (TG, p<0.001), triglycerides/high density lipoprotein cholesterol (TG/HDL-C, p<0.001), C-reactive protein (CRP, p<0.05), fasting insulin (p<0.001), Homeostasis Model Assessment - Insulin Resistance (HOMA-IR, p<0.001), alanine aminotransferase (ALT, p<0.001) and uric acid (p<0.001) compared to the control group. Baseline vitamin D was related to fasting insulin (R=-0.29, p=0.021), HOMA-IR (R=-0.30, p=0.016), HDL-C (R=0.29, p=0.020) and uric acid (R=-0.28, p=0.037) in the study group. Baseline chemerin was related to insulin at 30' (R=0.27, p=0.030), 60' (R=0.27, p=0.033), 90' (R=0.26, p=0.037) and 120' (R=0.26, p=0.040) during the oral glucose tolerance test (OGTT) and ALT (R=0.25, p=0.041) in the study group. Correlation between vitamin D and chemerin (R=-0.39, p=0.046) was found only in the control group. After six months of vitamin D supplementation a decrease in CRP (p<0.01), total cholesterol (p<0.05), ALT (p<0.01), glucose at 150' OGTT (p<0.05) was observed. Moreover, we noticed a tendency for negative association between 25(OH)D and chemerin levels (p=0.085). Multivariable backward linear regression models were build using baseline vitamin D, baseline chemerin and six months chemerin as the dependent variables. Our study confirmed that vitamin D has positive effect on metabolic profile in overweight and obese children. The relationship between vitamin D and chemerin is not clear, nevertheless we have observed a tendency to decrease chemerin concentrations after improving vitamin D status, even without a significant reduction in body fat mass.

Sections du résumé

Background
Vitamin D affects adipogenesis, oxidative stress, inflammation, secretion of adipocytokines, lipid metabolism and thermogenesis. Some researchers postulate that those effects could be exerted by the influence of vitamin D on chemerin levels.
Aim of the study
We aimed to investigate if there is a link between serum 25-hydroksyvitamin D [25(OH)D], chemerin and metabolic profile in overweight and obese children before and after vitamin D supplementation.
Material and methods
The prospective study included 65 overweight and obese children aged 9.08-17.5 years and 26 peers as a control. None of the patients in the study group had received vitamin D within the last twelve months before the study.
Results
The study group had lower baseline 25(OH)D (p<0.001) and higher chemerin (p<0.001), triglycerides (TG, p<0.001), triglycerides/high density lipoprotein cholesterol (TG/HDL-C, p<0.001), C-reactive protein (CRP, p<0.05), fasting insulin (p<0.001), Homeostasis Model Assessment - Insulin Resistance (HOMA-IR, p<0.001), alanine aminotransferase (ALT, p<0.001) and uric acid (p<0.001) compared to the control group. Baseline vitamin D was related to fasting insulin (R=-0.29, p=0.021), HOMA-IR (R=-0.30, p=0.016), HDL-C (R=0.29, p=0.020) and uric acid (R=-0.28, p=0.037) in the study group. Baseline chemerin was related to insulin at 30' (R=0.27, p=0.030), 60' (R=0.27, p=0.033), 90' (R=0.26, p=0.037) and 120' (R=0.26, p=0.040) during the oral glucose tolerance test (OGTT) and ALT (R=0.25, p=0.041) in the study group. Correlation between vitamin D and chemerin (R=-0.39, p=0.046) was found only in the control group. After six months of vitamin D supplementation a decrease in CRP (p<0.01), total cholesterol (p<0.05), ALT (p<0.01), glucose at 150' OGTT (p<0.05) was observed. Moreover, we noticed a tendency for negative association between 25(OH)D and chemerin levels (p=0.085). Multivariable backward linear regression models were build using baseline vitamin D, baseline chemerin and six months chemerin as the dependent variables.
Conclusions
Our study confirmed that vitamin D has positive effect on metabolic profile in overweight and obese children. The relationship between vitamin D and chemerin is not clear, nevertheless we have observed a tendency to decrease chemerin concentrations after improving vitamin D status, even without a significant reduction in body fat mass.

Identifiants

pubmed: 37152969
doi: 10.3389/fendo.2023.1143755
pmc: PMC10159269
doi:

Substances chimiques

Insulin 0
Triglycerides 0
Uric Acid 268B43MJ25
Vitamin D 1406-16-2
Vitamins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1143755

Informations de copyright

Copyright © 2023 Krajewska, Witkowska-Sędek, Rumińska, Kucharska, Stelmaszczyk-Emmel, Sobol, Majcher and Pyrżak.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

J Clin Endocrinol Metab. 2022 May 17;107(6):1541-1551
pubmed: 35240684
Am J Clin Exp Immunol. 2014 Feb 27;3(1):1-19
pubmed: 24660117
Obes Rev. 2013 Mar;14(3):245-62
pubmed: 23216632
J Nutr. 2010 May;140(5):987-91
pubmed: 20237070
Clin Chim Acta. 2021 Jun;517:41-47
pubmed: 33631197
Pediatrics. 2006 Jun;117(6):2065-73
pubmed: 16740849
J Clin Invest. 2011 May;121(5):1858-70
pubmed: 21490391
Int J Mol Sci. 2019 Jul 31;20(15):
pubmed: 31370263
Front Immunol. 2018 Nov 30;9:2772
pubmed: 30555465
Eur J Pediatr. 2011 May;170(5):599-609
pubmed: 20972688
Arch Med Sci. 2013 Apr 20;9(2):191-200
pubmed: 23671428
Medicine (Baltimore). 2016 Aug;95(35):e4583
pubmed: 27583869
Int J Vitam Nutr Res. 2014;84(1-2):98-107
pubmed: 25835240
J Bone Miner Res. 2010 Feb;25(2):222-34
pubmed: 19929432
Biomedicines. 2022 Mar 03;10(3):
pubmed: 35327393
J Clin Endocrinol Metab. 2008 Nov;93(11):4200-9
pubmed: 18697860
Pediatrics. 2016 Jul;138(1):
pubmed: 27335379
Horm Res Paediatr. 2014;82(2):107-12
pubmed: 25034315
Int J Mol Sci. 2022 Jan 16;23(2):
pubmed: 35055140
Glob Pediatr Health. 2021 May 27;8:2333794X211018352
pubmed: 34104694
Metabolites. 2019 Jun 30;9(7):
pubmed: 31262034
Endokrynol Pol. 2022;73(1):26-34
pubmed: 35119086
Metabolism. 2015 Jan;64(1):131-45
pubmed: 25497344
J Biol Chem. 2007 Sep 21;282(38):28175-88
pubmed: 17635925
J Pediatr Endocrinol Metab. 2012;25(1-2):83-7
pubmed: 22570955
Clin Med Insights Pediatr. 2019 Jun 05;13:1179556519853780
pubmed: 31217700
Eur J Endocrinol. 2019 Oct;181(4):439-450
pubmed: 31408845
J Pediatr Endocrinol Metab. 2016 Jul 1;29(7):777-81
pubmed: 27089407
Int J Mol Sci. 2020 Sep 11;21(18):
pubmed: 32932777
Adv Med Sci. 2017 Sep;62(2):383-386
pubmed: 28551507
Int J Obes (Lond). 2018 Oct;42(10):1743-1752
pubmed: 30030480
Eur J Clin Nutr. 1990 Jan;44(1):45-60
pubmed: 2354692
Adv Med Sci. 2021 Sep;66(2):270-278
pubmed: 34082283
J Exp Med. 2009 Jan 16;206(1):249-58
pubmed: 19114666
World Health Organ Tech Rep Ser. 1995;854:1-452
pubmed: 8594834
Nutrients. 2021 Jan 20;13(2):
pubmed: 33498461
ARYA Atheroscler. 2015 Feb;11(Suppl 1):102-8
pubmed: 26261457
Pediatrics. 2009 Sep;124(3):e371-9
pubmed: 19661053
Int J Obes (Lond). 2014 Jan;38(1):46-52
pubmed: 23736361
Curr Obes Rep. 2019 Dec;8(4):472-479
pubmed: 31691175
Int J Endocrinol Metab. 2019 Jan 07;17(1):e74255
pubmed: 30881469
J Pediatr (Rio J). 2014 Jan-Feb;90(1):28-34
pubmed: 24140383
Intern Emerg Med. 2013 Feb;8(1):33-40
pubmed: 21437585
Ann Agric Environ Med. 2017 Dec 23;24(4):636-639
pubmed: 29284239
Int J Mol Sci. 2019 Mar 05;20(5):
pubmed: 30841637
Arch Argent Pediatr. 2017 Apr 1;115(2):133-139
pubmed: 28318178
Metabolism. 2012 May;61(5):706-14
pubmed: 22136911
Int J Endocrinol. 2012;2012:173581
pubmed: 22966228
J Clin Endocrinol Metab. 2012 Jan;97(1):279-85
pubmed: 22072738
IUBMB Life. 2014 Mar;66(3):147-155
pubmed: 24638917
Arch Med Res. 2016 Oct;47(7):541-549
pubmed: 28262196
Menopause. 2018 May;25(5):574-578
pubmed: 29206770
Hum Biol. 1988 Oct;60(5):709-23
pubmed: 3224965
Stem Cells. 2013 Oct;31(10):2172-82
pubmed: 23766088
Biomedicines. 2022 Aug 07;10(8):
pubmed: 36009457
Hypertens Pregnancy. 2019 Aug;38(3):149-156
pubmed: 30922121
Front Endocrinol (Lausanne). 2018 May 31;9:246
pubmed: 29904370
Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):182-8
pubmed: 16284192
Horm Mol Biol Clin Investig. 2016 Apr 1;26(1):25-42
pubmed: 26910750
Horm Metab Res. 2020 Oct;52(10):732-741
pubmed: 33049785
Med Sci (Basel). 2022 Sep 05;10(3):
pubmed: 36135834
Front Endocrinol (Lausanne). 2019 Mar 01;10:103
pubmed: 30881343
Front Endocrinol (Lausanne). 2022 Jun 13;13:920340
pubmed: 35769088
J Pediatr Endocrinol Metab. 2018 Jan 26;31(2):127-135
pubmed: 29306931
Ther Adv Endocrinol Metab. 2014 Dec;5(6):166-89
pubmed: 25489472
Int J Food Sci Nutr. 2015 Mar;66(2):132-4
pubmed: 25657099
Eur J Clin Invest. 2010 Mar;40(3):277-80
pubmed: 20105226
J Pediatr (Rio J). 2021 May-Jun;97(3):273-279
pubmed: 33022267
Asian J Sports Med. 2010 Sep;1(3):151-8
pubmed: 22375203
Int J Womens Health. 2022 Feb 02;14:107-118
pubmed: 35140527
Nutr Metab Insights. 2021 May 26;14:11786388211018726
pubmed: 34103940
Nutrients. 2021 Dec 15;13(12):
pubmed: 34960039
Int J Environ Res Public Health. 2020 Oct 18;17(20):
pubmed: 33081030

Auteurs

Maria Krajewska (M)

Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Ewelina Witkowska-Sędek (E)

Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Małgorzata Rumińska (M)

Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Anna M Kucharska (AM)

Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Anna Stelmaszczyk-Emmel (A)

Department of Laboratory Diagnostics and Clinical Immunology of Developmental Age, Medical University of Warsaw, Warsaw, Poland.

Maria Sobol (M)

Department of Biophysics, Physiology and Pathophysiology, Medical University of Warsaw, Warsaw, Poland.

Anna Majcher (A)

Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Beata Pyrżak (B)

Department of Paediatrics and Endocrinology, Medical University of Warsaw, Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH